⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24806504 | 1.00 | — | — | |
| SCHEMBL20499041 | 1.00 | — | — | |
| SCHEMBL28976513 | 1.00 | — | — | |
| SCHEMBL22869363 | 1.00 | — | — | |
| SCHEMBL25776830 | 1.00 | — | — | |
| SCHEMBL16718823 | 0.82 | SLC1A2 (0.56) | — | |
| SCHEMBL16700128 | 0.82 | SLC1A2 (0.56) | — | |
| SCHEMBL16700781 | 0.82 | SLC1A2 (0.56) | — | |
| SCHEMBL30244762 | 0.77 | — | — | |
| SCHEMBL19508082 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250250284-A1 | MACROCYCLE COMPOUNDS USEFUL AS KRAS INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4551295-A1 | MACROCYCLE COMPOUNDS USEFUL AS KRAS INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025087431-A1 | PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES | 贝达药业股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| CN-119546613-A | Macrocyclic compounds useful as KRAS inhibitors | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4469164-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024169914-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| CN-111819173-B | CD73 inhibitors | 伊莱利利公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022095953-A1 | PYRIDAZINE ALKYNE COMPOUNDS AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2022095953-A1 | PYRIDAZINE ALKYNE COMPOUNDS AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-05-12 | — | — | WO | disclosed |
| CN-114437038-A | Pyridazine alkyne compound and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114315839-A | Pyrimidinedione compounds and use thereof | 武汉人福创新药物研发中心有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022068929-A1 | PYRIMIDINEDIONE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-04-07 | — | — | WO | disclosed |
| EP-3759096-B1 | CD73 INHIBITORS | LILLY CO ELI (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11028074-B2 | CD73 inhibitors | ELI LILLY AND COMPANY (US) | 2021-06-08 | — | — | US | disclosed |
| US-20210002257-A1 | CD73 INHIBITORS | ELI LILLY AND COMPANY | 2021-01-07 | — | — | US | disclosed |
| CN-111819173-A | CD73 inhibitor | 伊莱利利公司 | 2020-10-23 | — | — | CN | disclosed |